Different approach from many other VE studies, following HCW vaccinated vs unvaccinated, tested when exposed to a case, to assess VE against infection given exposure, consistent with our recommendations in sciencedirect.com/science/articl…
Also looked at infectiousness (proxied by Ct). Take home messages: fully vaccinated 65% (45-79) protected against infection given exposure. This is lower than other estimates of symptomatic or arbitrary mix of symptomatic and other cases, as expected.
(this was before Delta). The "all infections" outcome in many other studies is really not all, but all that are ascertained passively. This was active surveillance so gets a higher % of low/asymptomatic cases and thus expected to have lower VE (see the Vaccine paper for more)
2. We found 70(43-84)% VE against infection with any Ct<30 perhaps indicating infectiousness. 3. Median Ct ~5 lower for fully vaccinated (breakthru) cases vs. unvaccinated. Could mean shedding <10% as much virus, thus less transmissible.
4. Small numbers but interesting: Antigen test positivity was 80% in Ct<30 if not vaccinated, but only 31% in Ct<30 if vaccinated, perhaps indicating that infectivity was even lower than the Ct values indicate (if Ct is measuring more dead virus in vaxed cases).
Overall very encouraging for transmission reduction by mRNA vaccines, via a combo of preventing infection and reducing infectiousness. Obviously key to know if the same will be true with additional variants.
Correction to #4 above: thanks @vercheckt indeed the numbers given are for all PCR+ 32% (correctly rounded) of vaxed vs 80% of unvaxed were antigen test+
• • •
Missing some Tweet in this thread? You can try to
force a refresh
In which we show that earlier work by Rinta-Kokko et al on interpreting prevalence measures for vaccine efficacy generalizes to the COVID-19 case pubmed.ncbi.nlm.nih.gov/19490983/ and that the odds ratio for PCR+ in vax vs unvax persons swabbed at random
is under reasonable assumptions a lower bound on the vaccine's effect against transmission, the critical quantity for herd immunity that combines reduced risk of acquiring and shorter duration.
In contrast this statement is illogical “However, since we observed all notable SARS-CoV-2 features, including the optimized RBD and polybasic cleavage site, in related coronaviruses in nature, we do not believe that any type of laboratory-based scenario is plausible.”
This tweet got me thinking again about a topic that's been on my mind for the last several weeks and throughout the pandemic. In principle I fully agree with @flodebarre that people should evaluate arguments for logical soundness and consistency with facts, not who makes them.
But many people have asked me (most recently @AmyDMarcus) how thoughtful people should know whom to trust in getting information (science) and advice (for personal actions) and opinions (about policy) on a topic like COVID
Consistent with @flodebarre's tweet, my first response was you shouldn't trust anyone intrinsically, but should trust good arguments. As a scientist, that is how we are (or should be, there is still too much hero worship in our field) trained.
I and many other @cambridgeWG support proper investigation of SARS-CoV-2 origins including the lab leak hypothesis and continue to oppose many forms of GOF research but it is just fabrication to say we have made any statement as a group about work in Wuhan.
What we called for was a moratorium on GOF research until proper risk-benefit calculations can be done. Just as this pandemic was starting, two of us were strongly critical of how @NIH and @HHSGov evaluate GOF proposals msphere.asm.org/content/5/1/e0…, calling for much more transparency.
Really important @nytimes article on how easy access to vaccines remains a key issue not just hesitancy nytimes.com/2021/05/12/us/…. I’d add two points less explicit in article
1. People say that seeing others get vax without incident reduces their hesitancy. If so then each vaccine administered to those where access is the main problem can have a multiplier effect in overcoming hesitancy in others.
2. If we think of getting vaccinated like any other choice then hesitancy and ease of obtaining are two sides of same coin. If hard to get, a little hesitancy will stop. If easy to get, only the very hesitant won’t.
Great that attention is remaining focused on #AMR a big problem. cidrap.umn.edu/news-perspecti… . But the relentless claims that this is primarily or largely a problem of agriculture are not evidence-based.
Recent excellent genomic work from Prof Sharon Peacock's group, @MarcBonten's group among others has failed to find evidence of strong links between resistance in animals and resistance in clinical isolates. @BillHanage wrote about this mbio.asm.org/content/10/2/e…